Merck stops another Winrevair study early based on positive results from earlier PAH trial

Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form of high blood pressure in the lungs. The Phase 3 HYPERION study looked ...